HIV drug resistance testing is an important part of evaluating treatment options for people newly diagnosed with human immunodeficiency virus (HIV). The test identifies genetic changes in the virus that may reduce the effectiveness of certain antiretroviral medications. Understanding these changes helps healthcare professionals select appropriate treatment combinations based on an individual's resistance profile and medical history.
HIV treatment has advanced considerably, and antiretroviral therapy (ART) can suppress viral replication and help people with HIV maintain their health. However, some HIV strains develop resistance to particular medications, making certain treatments less effective. HIV drug resistance testing helps healthcare professionals identify these changes and choose suitable medications. Understanding when testing is recommended and how results influence treatment decisions is an important part of HIV management.
HIV drug resistance testing examines the genetic material of the virus to identify mutations associated with reduced sensitivity to antiretroviral medications. These mutations can occur naturally as HIV replicates or develop when viral replication continues during treatment, particularly when medication levels are insufficient. In some cases, a person may acquire HIV that already contains drug-resistant mutations.
The main purpose of resistance testing is to help healthcare professionals determine which medications are likely to be effective. The results are considered alongside the patient's treatment history, viral load, other medical conditions, and potential drug interactions.
Two common types of resistance testing are genotypic and phenotypic testing. Genotypic testing identifies specific genetic mutations linked to resistance and is commonly used when selecting initial HIV treatment or evaluating treatment failure. Phenotypic testing measures how well HIV grows in the presence of different antiretroviral drugs. It may be useful in selected complex cases involving extensive resistance.
Important aspects of HIV drug resistance testing include:
Genotypic testing: Detects mutations in HIV genetic sequences associated with resistance to specific medications.
Phenotypic testing: Evaluates the virus's susceptibility to antiretroviral drugs under laboratory conditions.
Treatment planning: Helps clinicians select an effective combination of medications based on available resistance information.
Treatment failure assessment: Helps identify resistance when viral load remains detectable or increases despite treatment.
Clinical interpretation: Requires professional evaluation because not every detected mutation affects all medications equally.
Resistance testing is generally recommended at HIV diagnosis or before starting treatment when indicated by current clinical guidelines. Treatment should not be unnecessarily delayed while waiting for results; healthcare professionals can begin an appropriate initial regimen and adjust it if the findings require changes.
HIV drug resistance test results provide information that helps healthcare professionals choose or modify antiretroviral therapy. The findings indicate whether specific mutations are associated with resistance to particular drug classes, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors.
The appropriate treatment depends on the resistance pattern, previous medication exposure, treatment adherence, other health considerations, and available medicines. A resistance test does not independently determine the entire treatment plan.
Several factors influence how results are used:
Selecting initial therapy: Results may help identify medications that are less likely to work because of transmitted resistance.
Reviewing existing treatment: When viral suppression is inadequate, testing can help explain whether resistance contributes to treatment failure.
Considering previous medications: A complete treatment history helps clinicians interpret current and historical resistance findings.
Assessing integrase resistance: Specific testing may be needed when resistance to integrase inhibitors is suspected or relevant to treatment history.
Monitoring treatment effectiveness: Viral load testing remains essential for assessing whether ART is successfully suppressing HIV.
Resistance testing has limitations. Some resistant viral populations may become difficult to detect after a person stops taking particular medications. Results can also be less informative when the viral load is too low for reliable testing. For these reasons, clinicians interpret test findings alongside previous resistance reports and the patient's treatment history.
People taking HIV medication should continue following their prescribed regimen unless their healthcare professional advises otherwise. Missed doses, medication interactions, and interruptions in treatment can affect viral suppression and may contribute to resistance in certain circumstances.
HIV drug resistance testing supports individualized treatment decisions, but it is only one component of comprehensive HIV care. Regular medical appointments, viral load monitoring, appropriate medication use, and communication with healthcare professionals help support long-term treatment effectiveness. With suitable therapy and consistent care, many people with HIV can achieve and maintain viral suppression.